Kymera Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Kymera Therapeutics
KYMR Stock  USD 34.03  0.46  1.33%   
Kymera Therapeutics financial statements provide useful quarterly and yearly information to potential Kymera Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Kymera Therapeutics financial statements helps investors assess Kymera Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Kymera Therapeutics' valuation are summarized below:
Gross Profit
-193.2 M
Market Capitalization
2.2 B
Enterprise Value Revenue
39.1079
Revenue
47.1 M
Earnings Share
(2.98)
There are over one hundred nineteen available fundamental ratios for Kymera Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to check Kymera Therapeutics' last-minute fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/19/2025, Market Cap is likely to drop to about 1.6 B. In addition to that, Enterprise Value is likely to drop to about 1.6 B

Kymera Therapeutics Total Revenue

44.36 Million

Check Kymera Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kymera Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 39.7 M, Interest Income of 39.9 M or Depreciation And Amortization of 7.7 M, as well as many indicators such as Price To Sales Ratio of 126, Dividend Yield of 0.0 or PTB Ratio of 3.79. Kymera financial statements analysis is a perfect complement when working with Kymera Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Kymera Therapeutics Correlation against competitors.
To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.

Kymera Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets536 M978 M268.8 M
Slightly volatile
Short and Long Term Debt Total92.1 M87.8 M21.6 M
Slightly volatile
Other Current Liabilities19.6 M35.1 M9 M
Slightly volatile
Total Current Liabilities73.5 M67.8 M36.2 M
Slightly volatile
Other Liabilities38.6 M32.5 M17.2 M
Slightly volatile
Property Plant And Equipment Net102.8 M97.9 M23.8 M
Slightly volatile
Current Deferred Revenue12.9 M13.6 M27.7 M
Slightly volatile
Accounts Payable4.9 M6 M3.3 M
Slightly volatile
Cash77.8 M120.3 M56.4 M
Slightly volatile
Non Current Assets Total491.2 M467.8 M90.1 M
Slightly volatile
Other Assets11 M10.5 M3.3 M
Slightly volatile
Cash And Short Term Investments405.8 M488.7 M207.4 M
Slightly volatile
Net Receivables899.6 K947 K1.6 M
Slightly volatile
Common Stock Shares Outstanding49.9 M75 M33 M
Slightly volatile
Liabilities And Stockholders Equity536 M978 M268.8 M
Slightly volatile
Non Current Liabilities Total67.2 M74.6 M77.9 M
Very volatile
Capital Lease Obligations92.1 M87.8 M21.6 M
Slightly volatile
Other Current Assets21.6 M20.6 M5.1 M
Slightly volatile
Total Liabilities165.9 M142.4 M115.7 M
Slightly volatile
Property Plant And Equipment Gross119.6 M113.9 M28.9 M
Slightly volatile
Total Current Assets389.7 M510.3 M200.2 M
Slightly volatile
Non Current Liabilities Other270.9 K285.2 K3.5 M
Pretty Stable
Net Working Capital275.9 M442.5 M145.6 M
Slightly volatile
Short Term Debt7 M13.1 M3.4 M
Slightly volatile
Property Plant Equipment15.4 M15.3 M8.3 M
Slightly volatile
Common Stock Total Equity5.5 K6.9 K4.6 K
Slightly volatile
Capital Surpluse726.3 M1 B545.3 M
Slightly volatile
Long Term Investments190 M362.2 M167.4 M
Pretty Stable
Common Stock6.2 K7 K4.6 K
Slightly volatile

Kymera Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization7.7 M7.4 M1.8 M
Slightly volatile
Interest Expense152.9 K249 K78.4 K
Slightly volatile
Selling General Administrative35.9 M63.5 M18.4 M
Slightly volatile
Other Operating Expenses169.9 M308.7 M88.9 M
Slightly volatile
Research Development133.2 M240.2 M70.1 M
Slightly volatile
Total Operating Expenses169.9 M308.7 M88.9 M
Slightly volatile
Reconciled Depreciation7.7 M7.4 M1.8 M
Slightly volatile
Cost Of Revenue228.3 M217.4 M44.4 M
Slightly volatile
Preferred Stock And Other Adjustments7.2 M8.1 M8.9 M
Slightly volatile
Non Operating Income Net Other7.8 M7.4 M2.3 M
Slightly volatile

Kymera Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation57.8 M55 M14.3 M
Slightly volatile
Begin Period Cash Flow63.5 M115.8 M33.1 M
Slightly volatile
Other Cashflows From Financing Activities24.2 M13.8 M41.4 M
Slightly volatile
Depreciation7.7 M7.4 M1.8 M
Slightly volatile
Capital Expenditures9.9 M12.8 M5.2 M
Slightly volatile
Change To Operating Activities4.6 M2.6 M2.7 M
Slightly volatile
Total Cash From Financing Activities639.3 M608.9 M153.5 M
Slightly volatile
End Period Cash Flow82.1 M126 M58.5 M
Slightly volatile
Change To Netincome42.8 M40.8 M12.4 M
Slightly volatile
Change To Liabilities4.3 M4.5 M13.2 M
Pretty Stable
Sale Purchase Of Stock3.7 M3.9 M191.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12664.1362335
Slightly volatile
Days Sales Outstanding6.987.343118.1851
Pretty Stable
Stock Based Compensation To Revenue1.231.16870.5173
Slightly volatile
Capex To Depreciation1.651.74125.0011
Slightly volatile
EV To Sales12363.4459323
Slightly volatile
Payables Turnover25.2624.055.793
Slightly volatile
Sales General And Administrative To Revenue1.231.34972.0283
Slightly volatile
Research And Ddevelopement To Revenue5.025.10389.1494
Slightly volatile
Capex To Revenue0.170.27270.1903
Pretty Stable
Cash Per Share5.696.51283.9294
Slightly volatile
Days Payables Outstanding14.9215.712.2 K
Slightly volatile
Net Debt To EBITDA0.140.15031.2469
Slightly volatile
Current Ratio4.77.52977.3179
Slightly volatile
Receivables Turnover47.2249.706457.52
Pretty Stable
Capex Per Share0.160.17110.1136
Slightly volatile
Revenue Per Share0.850.62730.4894
Slightly volatile
Interest Debt Per Share1.231.17280.389
Slightly volatile
Debt To Assets0.06050.08970.0447
Slightly volatile
Days Of Payables Outstanding14.9215.712.2 K
Slightly volatile
Ebt Per Ebit1.050.85560.9824
Slightly volatile
Long Term Debt To Capitalization0.03770.07380.0496
Very volatile
Quick Ratio4.97.52977.4404
Slightly volatile
Net Income Per E B T1.081.131.0078
Slightly volatile
Cash Ratio2.51.77465.5513
Slightly volatile
Days Of Sales Outstanding6.987.343118.1851
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.841.0661.0514
Pretty Stable
Fixed Asset Turnover0.460.4810.9893
Slightly volatile
Debt Ratio0.06050.08970.0447
Slightly volatile
Price Sales Ratio12664.1362335
Slightly volatile
Asset Turnover0.06370.04810.048
Slightly volatile

Kymera Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.6 B3 B1.8 B
Slightly volatile
Enterprise Value1.6 B3 B1.7 B
Slightly volatile

Kymera Fundamental Market Drivers

Cash And Short Term Investments488.7 M

Kymera Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Kymera Therapeutics Financial Statements

Kymera Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Kymera Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Kymera Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Kymera Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue13.6 M12.9 M
Total Revenue47.1 M44.4 M
Cost Of Revenue217.4 M228.3 M
Stock Based Compensation To Revenue 1.17  1.23 
Sales General And Administrative To Revenue 1.35  1.23 
Research And Ddevelopement To Revenue 5.10  5.02 
Capex To Revenue 0.27  0.17 
Revenue Per Share 0.63  0.85 
Ebit Per Revenue(5.56)(5.84)

Pair Trading with Kymera Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Kymera Stock

  0.68A Agilent TechnologiesPairCorr
  0.88ME 23Andme HoldingPairCorr

Moving against Kymera Stock

  0.79VALN Valneva SE ADRPairCorr
  0.73DVAX Dynavax TechnologiesPairCorr
  0.44EQ EquilliumPairCorr
  0.42VIGL Vigil NeurosciencePairCorr
  0.41DMAC DiaMedica TherapeuticsPairCorr
The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.
The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Kymera Stock Analysis

When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY